MUSIi001-A-1

B2M-KO-SFiPSC5

General#

Cell Line

hPSCreg Name
MUSIi001-A-1
Alternative name(s)
B2M-KO-SFiPSC5
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 11th August 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Faculty of Medicine Siriraj Hospital (MUSI)
Owner Faculty of Medicine Siriraj Hospital (MUSI)
Distributors
Derivation country Thailand

External Databases

BioSamples SAMEA9652868
CLO CLO_0103472

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research: allowed
Clinical: not allowed
Commercial: not allowed
Subclone of

Donor Information#

General Donor Information

Sex female
Ethnicity Thai

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Disease associated phenotypes no phenotypes
Family history N/A
Is the medical history available upon request? N/A
Is clinical information available? N/A

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46, XX
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA104627073

Ethics#

Also have a look at the ethics information for the parental line MUSIi001-A .
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation#

General

The source cell information can be found in the parental cell line MUSIi001-A.

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones The iPSC clone was picked manually according to morphology.
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
NANOG
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Score:
Marker Present Absent
mCpG
OCT4
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
alpha fetoprotein (AFP)
Yes
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
smooth muscle actin
Yes
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
Beta III Tubulin
Yes
Morphology

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XX
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification#

Genetic modifications not related to a disease
B2M (target)
Gene knock-out
15q21.1
The homozygous B2M knockout iPSC line provides a model for studying immune responses toward allogeneic grafts. In addition, the iPSC line can be used as a starting cell line for HLA-II knockout for developing the HLA-null hypoimmunogenic cell line for the application in allogeneic cell-based therapy.
CRISPR-associated (CRISPR/Cas) System